PL374045A1 - Zwiększenie pozyskiwania aktywnych białek - Google Patents

Zwiększenie pozyskiwania aktywnych białek

Info

Publication number
PL374045A1
PL374045A1 PL02374045A PL37404502A PL374045A1 PL 374045 A1 PL374045 A1 PL 374045A1 PL 02374045 A PL02374045 A PL 02374045A PL 37404502 A PL37404502 A PL 37404502A PL 374045 A1 PL374045 A1 PL 374045A1
Authority
PL
Poland
Prior art keywords
efficient recovery
refolded proteins
correctly refolded
proteins
correctly
Prior art date
Application number
PL02374045A
Other languages
English (en)
Inventor
Helmut M. Sassenfeld
Richard L.Jr. Remmele
Rebecca E. Mccoy
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23033913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL374045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of PL374045A1 publication Critical patent/PL374045A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Measurement Of Radiation (AREA)
PL02374045A 2001-02-23 2002-02-22 Zwiększenie pozyskiwania aktywnych białek PL374045A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27103301P 2001-02-23 2001-02-23

Publications (1)

Publication Number Publication Date
PL374045A1 true PL374045A1 (pl) 2005-09-19

Family

ID=23033913

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02374045A PL374045A1 (pl) 2001-02-23 2002-02-22 Zwiększenie pozyskiwania aktywnych białek

Country Status (20)

Country Link
US (2) US7157557B2 (pl)
EP (1) EP1366062B1 (pl)
JP (1) JP2005505494A (pl)
KR (1) KR20040052481A (pl)
CN (1) CN1547586A (pl)
AT (1) ATE517909T1 (pl)
AU (1) AU2002255600B2 (pl)
BG (1) BG108087A (pl)
CA (1) CA2438094C (pl)
CZ (1) CZ20032208A3 (pl)
EE (1) EE200300408A (pl)
ES (1) ES2370235T3 (pl)
HU (1) HUP0303246A2 (pl)
IL (1) IL157446A0 (pl)
MX (1) MXPA03007563A (pl)
PL (1) PL374045A1 (pl)
RU (1) RU2316563C2 (pl)
SK (1) SK10472003A3 (pl)
WO (1) WO2002068455A2 (pl)
ZA (1) ZA200305909B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157446A0 (en) * 2001-02-23 2004-03-28 Immunex Corp Immunex Corp Increased recovery of active proteins
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
AU2005310305A1 (en) * 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
US20090232808A1 (en) * 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
EP1888637A2 (en) 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
ES2553160T3 (es) * 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
AR062069A1 (es) 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
ES3006441T3 (en) * 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
EP3366692A1 (en) 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9353165B2 (en) * 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
SI2895188T1 (en) 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
JP7644706B2 (ja) 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
KR20230124578A (ko) 2020-12-22 2023-08-25 암젠 인크 세포 배양 방법
WO2025128536A1 (en) * 2023-12-14 2025-06-19 Genentech, Inc. Disulfide isoform modulation
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US4766205A (en) 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
EP0293785A3 (en) * 1987-05-29 1990-05-02 Oncogen Limited Partnership Cloning and expression of simian transforming growth factor-ss1
US4970067A (en) * 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU648214B2 (en) * 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
FI951541A0 (fi) * 1993-08-04 1995-03-31 Ciba Geigy Ag Suurimolekyylipainoinen desulfatohirudiini
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
AU2603995A (en) * 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
AU3111995A (en) 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) * 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
IL157446A0 (en) * 2001-02-23 2004-03-28 Immunex Corp Immunex Corp Increased recovery of active proteins

Also Published As

Publication number Publication date
US7544784B2 (en) 2009-06-09
US20020182665A1 (en) 2002-12-05
RU2316563C2 (ru) 2008-02-10
RU2003127830A (ru) 2005-04-10
AU2002255600B2 (en) 2008-01-24
BG108087A (bg) 2005-04-30
US20070270577A1 (en) 2007-11-22
HK1059267A1 (en) 2004-06-25
SK10472003A3 (sk) 2004-03-02
HUP0303246A2 (hu) 2003-12-29
ZA200305909B (en) 2004-06-04
EP1366062A2 (en) 2003-12-03
EP1366062B1 (en) 2011-07-27
KR20040052481A (ko) 2004-06-23
MXPA03007563A (es) 2003-12-11
CA2438094C (en) 2011-10-11
WO2002068455A2 (en) 2002-09-06
IL157446A0 (en) 2004-03-28
ATE517909T1 (de) 2011-08-15
CZ20032208A3 (cs) 2004-01-14
US7157557B2 (en) 2007-01-02
WO2002068455A3 (en) 2003-09-18
ES2370235T3 (es) 2011-12-13
JP2005505494A (ja) 2005-02-24
CN1547586A (zh) 2004-11-17
CA2438094A1 (en) 2002-09-06
EE200300408A (et) 2003-12-15

Similar Documents

Publication Publication Date Title
PL374045A1 (pl) Zwiększenie pozyskiwania aktywnych białek
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
EP1654378A4 (en) METHODS OF CHEMICAL SYNTHESIS OF CHIMERIC PROTEINS OF IMMUNOGLOBULINS
EP1568710A3 (en) Antibody purification method
WO2003102132A3 (en) Non-affinity purification of proteins
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
MXPA04001547A (es) Proteina de leptina porcina, antisentido y anticuerpo.
DE60228603D1 (de) Antigene und vektoren für impfung
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
DE60025704D1 (de) Das goodpasture-antigen bindende protein
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
GB0119015D0 (en) A fusion protein
AU8405798A (en) A swine hepatitis e virus and uses thereof
WO2004053117A3 (en) Serine protease
WO2002062964A3 (en) Ap1 amine oxidase variants
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2001096593A3 (en) Novel motor proteins and methods for their use
WO2003022883A3 (de) Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems
WO2002038765A3 (en) Dna encoding bovine immunoglobulin a inducing protein and uses therefor
WO2004035733A3 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
WO2003012120A3 (en) Lp354 mammalian secreted protein
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
AU2002257075A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)